reports
- Jonathan Moreland
- Jonathan Moreland
NewtekOne, Inc. to Report Fourth Quarter 2025 Results and Host a Confe...
NewtekOne, Inc. to Report Fourth Quarter 2025 Results and Host a Conference Call on Thursday, January 29, 2026 BOCA RATON, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT) will report its fourth quarter 2025 financial results after the market closes on Thursday, January 29, 2026. A conference call to discuss these results will be hosted by Barry Sloane, Chief Executive Officer, and Frank DeMaria, Chief Financial Officer, at 4:30 pm ET on Thursday, January 29, 2026. Please note, to receive a dial-in number for the conference call or to listen to the webcast, interes...
NewtekOne, Inc. Announces Extension of Exchange Offer for its Notes du...
NewtekOne, Inc. Announces Extension of Exchange Offer for its Notes due 2026 BOCA RATON, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (“NewtekOne”) today announced that the expiration date with respect to its previously announced offer to exchange (the “Exchange Offer”) its outstanding 5.50% Notes due 2026 (the “Old Notes”) for an equal principal amount of newly issued 8.50% Fixed Rate Senior Notes due 2031 (the “New Notes”) has been extended to January 23, 2026 in order to provide holders of Old Notes additional time to participate in the Exchange Offer and exchange their Old ...
- Jonathan Moreland
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
MOD MODINE MANUFACTURING COMPANY
LTC LTC PROPERTIES INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LMNR LIMONEIRA CO.
DAKT DAKTRONICS INC.
CGNX COGNEX CORPORATION
CASY CASEY'S GENERAL STORES INC.
CALX CALIX NETWORKS
AZO AUTOZONE INC.
ADC AGREE REALTY CORPORATION
PAR PAR TECHNOLOGY CORP.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
PLBC PLUMAS BANCORP
CLPR CLIPPER REALTY
BOMN BOSTON OMAHA
UA UNDER ARMOUR
NKE INC.
ESQ NIKE INC. CLASS B
FGBI ESQUIRE FINANCIAL HOLDINGS
KOD FIRST GUARANTY BANCSHARES
GRX KODIAK SCIENCES
PHR THE GABELLI HEALTHCARE & WELLNESSRX TRUST
JYNT PHREESIA
ALT THE JOINT
COO ALTIMMUNE INC
APG THE COOPER COMPANIES INC.
ZNTL API GROUP CORP
IMNM ZENTALIS PHARMACEUTICALS
IVFH IMMUNOME
TMC INNOVATIVE FOOD HLDG
WRB TMC THE METALS CO INC
LUCY W.R. BERKLEY CORPORATION
PMCB INNOVATIVE EYEWEAR INC
GLSI PHARMACYTE BIOTECH INC
MAIA GREENWICH LIFESCIENCES INC
GTE MAIA BIOTECHNOLOGY INC
SUNS GRAN TIERRA ENERGY INC.
GF SUNRISE REALTY TRUST
MPTI THE NEW GERMANY FUND
INC.
M-TRON INDUSTRIES
INC.
- Jonathan Moreland
NewtekOne, Inc. Posts Investor Day Presentation and Provides 2026 EPS ...
NewtekOne, Inc. Posts Investor Day Presentation and Provides 2026 EPS Guidance Range of $2.15-$2.55 BOCA RATON, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (the “Company” or “NewtekOne”) (NASDAQ: NEWT) has posted to the Investor Relations section of its website () an investor presentation for its previously announced “2026 Analyst and Investor Day” event to be held on January 8, 2026 at 12:00 PM. In addition to hosting investors and analysts in person at the Company’s Boca Raton headquarters, the event is being webcasted live. To access the live webcast, participants should re...
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial C...
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 prior lines of therapy* Analysis of data from all-comer subjects with serous subtype and ≤2 prior lines of ...
- Jonathan Moreland
- Jonathan Moreland
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase ...
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026 WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predic...
- Jonathan Moreland
WHF WHITEHORSE FINANCE INC.
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
SPG SIMON PROPERTY GROUP INC.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
LTC LTC PROPERTIES INC.
HNRG HALLADOR ENERGY CO.
GOGO GOGO INC.
DAKT DAKTRONICS INC.
CUBE CUBESMART
AZO AUTOZONE INC.
ASA ASA
ADC AGREE REALTY CORPORATION
WVE WAVE LIFE SCIENCES
IGR CBRE CLARION GLOBAL REAL ESTAT
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
CLPR CLIPPER REALTY
BOMN BOSTON OMAHA
UA UNDER ARMOUR
NKE INC.
ULBI NIKE INC. CLASS B
FGBI ULTRALIFE
KOD FIRST GUARANTY BANCSHARES
EML KODIAK SCIENCES
MIDD THE EASTERN COMPANY
PHR THE MIDDLEBY CORPORATION
DHC PHREESIA
ALT DIVERSIFIED HEALTHCARE TRUST
COO ALTIMMUNE INC
AZYO THE COOPER COMPANIES INC.
DLHC AZIYO BIOLOGICS
IMNM DALEIGH HOLDINGS CORP
WRB IMMUNOME
MAIA W.R. BERKLEY CORPORATION
KVUE MAIA BIOTECHNOLOGY INC
GTE KENVUE INC
NBBK GRAN TIERRA ENERGY INC.
SUNS NB BANCORP INC.
ASST SUNRISE REALTY TRUST
MPTI ASSET ENTITIES INC.
M-TRON INDUSTRIES
INC.
- Jonathan Moreland
LTC LTC PROPERTIES INC.
ASA ASA
UA UNDER ARMOUR
FGBI INC.
GRX FIRST GUARANTY BANCSHARES
ANNX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
WRB ANNEXON
LUCY W.R. BERKLEY CORPORATION
PROP INNOVATIVE EYEWEAR INC
SUNS PRAIRIE OPERATING CO.
GF SUNRISE REALTY TRUST
FG THE NEW GERMANY FUND
INC.
F AND G ANNUITIES AND LIFE
INC.
- Jonathan Moreland
- Jonathan Moreland
AAON AAON INC.
WHF WHITEHORSE FINANCE INC.
SPG SIMON PROPERTY GROUP INC.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
HNRG HALLADOR ENERGY CO.
GOGO GOGO INC.
CUBE CUBESMART
CLFD CLEARFIELD INC.
AZO AUTOZONE INC.
ASA ASA
NB NIOCORP DEVELOPMENTS LTD
QTA QUATERRA RESOURCES INC.
WVE WAVE LIFE SCIENCES
IGR CBRE CLARION GLOBAL REAL ESTAT
WMG WARNER MUSIC GROUP CORP.
NKE NIKE INC. CLASS B
DIS THE WALT DISNEY COMPANY
ULBI ULTRALIFE
ELAN ELANCO ANIMAL HEALTH INC.
KOD KODIAK SCIENCES
EML THE EASTERN COMPANY
MIDD THE MIDDLEBY CORPORATION
PHR PHREESIA
DHC DIVERSIFIED HEALTHCARE TRUST
ALT ALTIMMUNE INC
COO THE COOPER COMPANIES INC.
RZLT REZOLUTE
AZYO INC.
DLHC AZIYO BIOLOGICS
AMR DALEIGH HOLDINGS CORP
BMEA ALPHA METALLURGICAL RESOURCES INC
WRB BIOMEA FUSION
NUVL INC.
MAIA W.R. BERKLEY CORPORATION
KVUE NUVALENT INC
GTE MAIA BIOTECHNOLOGY INC
NBBK KENVUE INC
SI GRAN TIERRA ENERGY INC.
ASST NB BANCORP INC.
MPTI SHOULDER INNOVATIONS INC
ASSET ENTITIES INC.
M-TRON INDUSTRIES
INC.
NewtekOne, Inc. to Host Investor/Analyst Day on January 8, 2026
NewtekOne, Inc. to Host Investor/Analyst Day on January 8, 2026 BOCA RATON, Fla., Dec. 23, 2025 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (the “Company” or “NewtekOne”) (NASDAQ: NEWT) will be hosting an Analyst and Investor Day on January 8, 2026, at its Boca Raton, Florida headquarters and webcasting the event for individuals unable to participate in person. To access the webcast, participants should register online at . A replay of the event with the corresponding presentation materials will be available on NewtekOne’s website shortly after the live event and will be available for a period of...
- Jonathan Moreland
- Jonathan Moreland
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ong...
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global co...
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase ...
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-r...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.